Research and Markets: Microalbuminuria - Pipeline Review, H1 2013

Tue Jul 16, 2013 5:43am EDT

* Reuters is not responsible for the content in this press release.

Research and Markets: Microalbuminuria - Pipeline Review, H1 2013

Research and Markets ( has announced the addition of the "Microalbuminuria - Pipeline Review, H1 2013" report to their offering.

This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Microalbuminuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for

The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts.


- A snapshot of the global therapeutic scenario for Microalbuminuria.

- A review of the Microalbuminuria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Microalbuminuria pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Key Topics Covered:

1. List of Tables

1.1 List of Figures

2. Introduction


2.2 Microalbuminuria Overview

2.3 Therapeutics Development

3. An Overview of Pipeline Products for Microalbuminuria

3.1 Microalbuminuria Therapeutics under Development by Companies

3.2 Mid Clinical Stage Products

3.3 Comparative Analysis

3.4 Early Clinical Stage Products

3.5 Comparative Analysis

3.6 Microalbuminuria Therapeutics - Products under Development by Companies

4. Companies Involved in Microalbuminuria Therapeutics Development

4.1 Bristol-Myers Squibb Company

4.2 FibroGen, Inc.

4.3 Microalbuminuria - Therapeutics Assessment

5. Assessment by Monotherapy Products

5.1 Assessment by Route of Administration

5.2 Assessment by Molecule Type

6. Drug Profiles

7. Appendix

For more information visit

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.